This study confirmed decrease in SEC13 expression with all cancer stages (II, III, IV); while SMAD7 tended to be especially highly expressed in GC patients with stage IV, which could explain the significant negative correlation between SEC13 and SMAD7. Here, SEC13 is linked to gastric cancer.